Wyeth and Elan Pharma International Limited
On May 14, 2008, INTELLECT NEUROSCIENCES, INC. (OTCBB: ILNS) ("Intellect") entered into a License Agreement (the "Agreement") by and among Intellect and AHP MANUFACTURING BV, acting through its Wyeth Medica Ireland Branch, ("Wyeth") and ELAN PHARMA INTERNATIONAL LIMITED ("Elan")to provide Wyeth and Elan (the "Licensees") with certain license rights under certain of Intellect's patents and patent applications (the "Licensed Patents") relating to certain antibodies that may serve as potential therapeutic products for the treatment for Alzheimer's Disease (the "Licensed Products") and for the research, development, manufacture and commercialization of Licensed Products.

Pursuant to the Agreement, Intellect grants the Licensees (i) a co-exclusive license (co-exclusive as to each Licensee) under the Licensed Patents to research, develop, manufacture and commercialize Licensed Products comprising any polypeptide sharing substantial similarity with bapineuzumab and any other polypeptide comprising sequences substantially identical to the complementarity determining region of the 3D6 immunoglobin (a) light chain variable region and/or (b) the heavy chain variable region ("Bapineuzumab Products") in the Field in the Territory (as such terms are defined in the Agreement) and (ii) a non-exclusive license under the Licensed Patents to research, develop, manufacture and commercialize Licensed Products (other than Bapineuzumab Products) in the Field in the Territory.

CHDI, Inc.
In September 2007 we entered into an agreement with CHDI, Inc., a non-profit organization pursuing the discovery and development of drugs to prevent or slow the progression of Huntington's disease (HD), under which CHDI will assess Intellect's OXIGON(TM) as a potential therapy for HD. CHDI has access to a variety of relevant research tools, including in vitro and in vivo assays and animal models. Intellect has completed Phase I clinical trials for OXIGON(TM) in elderly healthy volunteers.